Background and ObjectiveDoxorubicin (DOX) is a widely used chemotherapeutic agent with dose‐dependent cardiotoxic effects. It is of great clinical significance to identify a cytoprotective agent which can attenuate DOX cardiotoxicity without affecting its anti‐tumor efficacy. Resveratrol (Rev) is a plant‐derived polyphenol shown to exert cardioprotective effects in DOX‐treated cardiomyocytes, but its mechanisms of cardioprotection remain partially understood. We tested the hypothesis that Rev protects against DOX‐induced cardiomyocyte injury by inhibiting excessive degradation of mitochondria through the autophagy‐lysosome pathway (mitophagy).
MethodsH9C2 cardiac myoblasts were cultured under four conditions: 0.5 uM DOX, 5 uM Rev, 5 uM Rev + 0.5 uM DOX, and Ethanol (control). Propidium Iodide (PI) staining was used to assess necrotic cell death. Western Blotting was used to measure PARP cleavage, an apoptotic marker. Mitophagy was assessed via cellular infection with Adenovirus encoding MitoRosella, a novel dual fluorescent pH sensitive mitophagy reporter.
ResultsDOX induced cardiomyocyte death as measured by PI positive cell and PARP cleavage, which was associated with increased mitophagy as assessed by the MitoRosella reporter. Pre‐treatment of cells with Rev not only attenuated DOX‐induced cell death but also inhibited DOX‐induced excessive mitophagy (Fig.1 C‐D). Rev alone had no effect on mitophagy (Fig.1 A‐B).imageConclusionThe cardioprotective effect of Resveratrol is associated with a significant reduction in DOX‐induced mitophagy in cardiomyocytes, suggesting the excessive destruction of mitochondria as a potential cardiotoxic mechanism of DOX.